Literature DB >> 14739620

Inhibition of angiogenic initiation and disruption of newly established human vascular networks by juice from Morinda citrifolia (noni).

Conrad A Hornick1, Amy Myers, Halina Sadowska-Krowicka, Catherine T Anthony, Eugene A Woltering.   

Abstract

noni, the juice of the fruit from the Morinda citrifolia plant, has been used for centuries as a medicinal agent. We tested the effects of noni juice in a three-dimensional fibrin clot matrix model using human placental vein and human breast tumor explants as sources for angiogenic vessel development. Noni in concentrations of 5% (vol/vol) or greater was highly effective in inhibiting the initiation of new vessel sprouts from placental vein explants, compared with initiation in control explants in media supplemented with an equivalent amount of saline. These concentrations of noni were also effective in reducing the growth rate and proliferation of newly developing capillary sprouts. When used at a concentration of 10% in growth media, noni was able to induce vessel degeneration and apoptosis in wells with established capillary networks within a few days of its application. We also found that 10% noni juice in media was an effective inhibitor of capillary initiation in explants from human breast tumors. In tumor explants which did show capillary sprouting, the vessels rapidly degenerated (2-3 days) in those exposed to media supplemented with 10% noni.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14739620     DOI: 10.1023/B:AGEN.0000011800.04507.4b

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  9 in total

1.  Using quality of life measures in a Phase I clinical trial of noni in patients with advanced cancer to select a Phase II dose.

Authors:  Brian F Issell; Carolyn C Gotay; Ian Pagano; Adrian A Franke
Journal:  J Diet Suppl       Date:  2009

2.  Damnacanthal, a noni component, exhibits antitumorigenic activity in human colorectal cancer cells.

Authors:  Thararat Nualsanit; Pleumchitt Rojanapanthu; Wandee Gritsanapan; Seong-Ho Lee; Darunee Lawson; Seung Joon Baek
Journal:  J Nutr Biochem       Date:  2011-08-17       Impact factor: 6.048

3.  Pharmacokinetic pilot study of the antiangiogenic activity of standardized platycodi radix.

Authors:  Emma M Twiner; Zhijun Liu; Jeffrey Gimble; Ying Yu; Frank Greenway
Journal:  Adv Ther       Date:  2011-10       Impact factor: 3.845

4.  Enterostatin inhibition of angiogenesis: possible role of pAMPK and vascular endothelial growth factor A (VEGF-A).

Authors:  M Park; J Lyons; H Oh; Y Yu; E A Woltering; F Greenway; D A York
Journal:  Int J Obes (Lond)       Date:  2008-02-26       Impact factor: 5.095

5.  Antitumor activity of fermented noni exudates and its fractions.

Authors:  Jinhua Li; Leng-Chee Chang; Marisa Wall; D K W Wong; Xianzhong Yu; Yanzhang Wei
Journal:  Mol Clin Oncol       Date:  2012-09-19

6.  An assay to measure angiogenesis in human fat tissue.

Authors:  Frank L Greenway; Zhijun Liu; Ying Yu; Mary K Caruso; Andrew T Roberts; John Lyons; Joshua E Schwimer; Alok K Gupta; Drake E Bellanger; Thomas S Guillot; Eugene A Woltering
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

7.  Morinda citrifolia (Noni) Juice Augments Mammary Gland Differentiation and Reduces Mammary Tumor Growth in Mice Expressing the Unactivated c-erbB2 Transgene.

Authors:  William P Clafshenkel; Tracy L King; Mary P Kotlarczyk; J Mark Cline; Warren G Foster; Vicki L Davis; Paula A Witt-Enderby
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-26       Impact factor: 2.629

8.  A long-term investigation of the anti-hepatocarcinogenic potential of an indigenous medicine comprised of Nigella sativa, Hemidesmus indicus and Smilax glabra.

Authors:  S S Iddamaldeniya; M I Thabrew; S M D N Wickramasinghe; N Ratnatunge; M G Thammitiyagodage
Journal:  J Carcinog       Date:  2006-05-09

9.  The Role of Endophytic Fungi in the Anticancer Activity of Morinda citrifolia Linn. (Noni).

Authors:  Yougen Wu; Sisay Girmay; Vitor Martins da Silva; Brian Perry; Xinwen Hu; Ghee T Tan
Journal:  Evid Based Complement Alternat Med       Date:  2015-12-10       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.